Cipla, incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 77400.61 Crore) operating in Pharmaceuticals sector.
Cipla key Products/Revenue Segments include Pharmaceuticals, Royalty Income, Other Operating Revenue, Export Incentives and Scrap for the year ending 31-Mar-2022.
Financials
For the quarter ended 31-12-2022, the company has reported a Consolidated Total Income of Rs 5924.53 Crore, down -.45 % from last quarter Total Income of Rs 5951.49 Crore and up 6.36 % from last year same quarter Total Income of Rs 5570.15 Crore. Company has reported net profit after tax of Rs 808.05 Crore in latest quarter.
The company’s top management includes Dr.Y K Hamied, Ms.Punita Lal, Mr.Adil Zainulbhai, Dr.Peter Mugyenyi, Mr.Robert Stewart, Mr.P R Ramesh, Mr.Ashok Sinha, Mr.S Radhakrishnan, Mr.Umang Vohra, Ms.Samina Hamied, Mr.M K Hamied, Dr.Mandar Vaidya. Company has Walker Chandiok & Co. LLP as its auditors. As on 31-12-2022, the company has a total of 81 Crore shares outstanding.
The company has been witnessing increased cost pressures owing to an increase in R&D, marketing and promotional expenses and an increase in the number of partnered products. Hence, the brokerage maintains sales CAGR but has reduced its earnings estimates down.
Promoter/FII Holdings
Promoters held 33.61 per cent stake in the company as of 31-Dec-2022, while FIIs owned 28.39 per cent, DIIs 20.76 per cent.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.